immediate wealth creation.
a long wait for an uncertain payoff.
a long wait for a high probability payoff.
a large payoff in the short term with rapidly decreasing wealth generation in the longer run.
81. One of the distinguishing differences between the two sources of internal corporate venturing (autonomous strategic
behavior and induced strategic behavior) is whether the innovation process:
is encouraged through a bottom-up or top-down process.
is encouraged by a product champion or an entrepreneur external to the organization.
relies on internal structure or existing strategy to encourage innovation.
is in a large or small organization.
82. The main risk in a strategic alliance is that:
the alliance will not result in a successful innovation.
critical employees will be hired away by the strategic partner.
one partner will use the other partner’s knowledge and use it to enhance its own competitive abilities.
the partners will lose control over their internal processes.
83. Blixin Concrete Products, an established firm, is seeking a technologically advanced partner for a strategic alliance. If
the potential partner is a new entrepreneurial venture, the main benefit the Blixin Concrete can offer is probably:
research and development competencies.
84. A major barrier to the use of cross-functional teams is:
excessive individualism of creative people.
lack of communication skills of technical people.
independent frames of reference of team members.
lack of social capital by team members.
85. Roland has developed and patented an inexpensive and organic way to enhance the fertility of clay soils without the
addition of chemical fertilizers. But established agricultural chemical companies have rejected his proposals. After 6
months of promoting his invention during his time off from his regular job, Roland has decided to set his dream aside.
Roland lacks a key characteristic of successful entrepreneurs, which is:
the ability to identify opportunities.
passion for his invention.
86. Why have large pharmaceutical companies been forming alliances with biotechnology companies?
To evade legislative restrictions on drug research in the United States
To develop new products and bring them to market
Because both firms had declining profitability and needed cash infusions from other firms
In order to gain absorptive capacity